A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia

Genes and Immunity

Volumn 9, Issue 8, 2008, Pages 659-667

  Paladini, F ^a   Cocco, E ^a   Cauli, A ^b   Cascino, I ^c   Vacca, A ^b   Belfiore, F ^c   Fiorillo, M T ^a   Mathieu, A ^b   Sorrentino, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; LIPOPOLYSACCHARIDE; MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

3' UNTRANSLATED REGION; ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; FEMALE; FOUNDER EFFECT; GENE FREQUENCY; GENE MAPPING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; DOWN-REGULATION; FEMALE; FOUNDER EFFECT; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA-B27 ANTIGEN; HUMANS; ITALY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SPONDYLITIS, ANKYLOSING; VASOACTIVE INTESTINAL PEPTIDE;

EID: 57249086244     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2008.60     Document Type: Article

References (41)

1. Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 2002; 109: 199-208.
2. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 1995; 92: 2939-2943.
3. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: A cytokine rather than a neuropeptide? FASEB J 2004; 18: 1325-1334.
4. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006; 107: 3632-3638.
5. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 2006; 131: 1799-1811.
6. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+, CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 2006; 54: 864-876.
7. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Martin J, Pozo D, Ganea D et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci 2006; 1070: 276-281.
8. Martyínez C, Arranz A, Juarranz Y, Abad C, García-Gómez M, Rosignoli F et al. PAC1 receptor: Emerging target for septic shock therapy. Ann NY Acad Sci 2006; 1070: 405-410.
9. Tunçel N, Sener E, Cerit C, Karasu U, Gürer F, Sahintürk V et al. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: Brain microdialysis, behavior, and microscopy. Peptides 2005; 26: 827-836.
10. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195-200.
11. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2001; 166: 2522-2530.
12. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973; 40: 904-907.
13. Benjamin R, Parham P. Guilty by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990; 11: 137-142.
14. Ramos S, Lopez de Castro JA. HLA-B27 and the pathogenesis of spondyloarthropathies. Tissue Antigens 2002; 60: 191-205.
15. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL et al. Susceptibility to ankylosing spondylitis in twins: The role of genes, HLA, and the environment. Arthritis Rheum 1997; 40: 1823-1828.
16. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 2001; 13: 265-272.
17. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases. Nat Genet 1999; 23: 397-404.
18. Lampis R, Morelli L, Congia M, Macis MD, Mulargia A, Loddo M et al The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases. Hum Mol Genet 2000; 9: 2959-2965.
19. Fiorillo MT, Cauli A, Carcassi C, Bitti PP, Vacca A, Passiu G et al Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum 2003; 48 1385-1389.
20. Paladini F, Cauli A, Punzi L, Taccari E, Lapadula G, Scarpa R et al Distribution of HLA-B27 subtypes in Sardinia and Continental Italy and their association with spondyloarthropathies. Arthritis Rheum 2005; 52: 3319-3321.
21. Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT et al. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum 2007; 56: 2640-2651.
22. Hulsmeyer M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A et al. Dual HLA-B27 subtype-dependent conformation of a self-peptide. J Exp Med 2004; 199: 271-281.
23. Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8(+) T cell autoreactivity to an HLA-B27 restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest 2000; 106: 47-53.
24. Epstein MP, Allen AS, Satten GA. A simple and improved correction for population stratification in case-control studies. Am J Hum Gen 2007; 80: 921-930.
25. Schirru E, Corona V, Usai-Satta P, Scarpa M, Cucca F, De Virgiliis S et al. Decline of lactase activity and C/T-13910 variant in Sardinian childhood. J Pediatr Gastroenterol Nutr 2007; 45: 503-506.
26. Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by down-regulating nuclear factor kappaB-dependent transcriptional activity. Biochem Biophys Res Commun 2003; 302: 275-283.
27. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 1999; 162: 1200-1205.
28. Persson E, Lerner UH. The neuropeptide VIP potentiates IL-6 production induced by pro-inflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. Biochem Biophys Res Commun 2005; 335: 705-711.
29. Wang HY, Jiang XM, Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol 2000; 104: 68-78.
30. Fabricius D, O'Dorisio, MS, Blackwell S, Jahrsdorfer B. plasmacytoid dendritic cell function: Inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 2006; 177: 5920-5927.
31. Foster N, Lea SR, Preshaw PM, Taylor JJ. Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 2007; 81: 893-903.
32. Pei L. Molecular cloning of a novel transcriptional repressor protein of the rat type 1 vasoactive intestinal peptide receptor gene. J Biol Chem 1998; 273: 19902-19908.
33. Dorsam G, Goetzl EJ. Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor lkaros. J Biol Chem 2002; 277: 13488-13493.
34. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis. Arthritis Rheum 2008; 58 1010-1019.
35. Barreau C, Paillard L, Osbome HB. Free in PMC AU-rich elements and associated factors: Are there unifying principles? Nucleic Acids Res 2005; 33: 7138-7150.
36. Fialcowitz EJ, Brewer BY, Keenan BP, Wilson GMJ. A hairpin-like structure within an AU-rich mRNA-destabdizing element regulates trans-factor binding selectivity and mRNA decay kinetics. J Biol Chem 2005; 280: 22406-22417.
37. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med 2000; 6: 637-641.
38. Khabar KS. The AU-rich transcriptome: More than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005; 25: 1-10.
39. Mathieu A, Cauli A, Fiorillo MT, Sorrentino R. HLA-B27 and ankylosing spondylitis geographic distribution versus malaria endemic: Casual or causal liaison? Ann Rheum Dis 2008; 67: 138-140.
40. Sotgiu S, Sannella AR, Conti B, Arru G, Fois ML, Sanna A et al. Multiple sclerosis and anti-Plasmodium falciparum innate immune response. J Neuroimmunol 2007; 185: 201-207.
41. Freson K, Hashimoto H, Thys C, Wittevrongel C, Danloy S, Morita Y et al. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest 2004; 113: 905-912.